Litigation Details for Cephalon, Inc. v. Fresenius Kabi USA, LLC (D. Del. 2015)

Cephalon, Inc. v. Fresenius Kabi USA, LLC (D. Del. 2015)

Docket		Date Filed	2015-06-24
Court	District Court, D. Delaware	Date Terminated	2016-07-29
Cause	35:271 Patent Infringement	Assigned To	Leonard Philip Stark
Jury Demand	None	Referred To
Parties	FRESENIUS KABI USA, LLC
Patents	8,344,006
Attorneys	Assad H. Rajani
Firms	Phillips, Goldman, McLaughlin & Hall, P.A.
Link to Docket	External link to docket

Details for Cephalon, Inc. v. Fresenius Kabi USA, LLC (D. Del. 2015)

Date Filed	Document No.	Description	Snippet	Link To Document
2015-06-24				External link to document
2015-06-24	4		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,344,006. (klc) (Entered: 06…2015 29 July 2016 1:15-cv-00536 830 Patent None District Court, D. Delaware	External link to document
2015-06-24	73		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,344,006. (ntl) (Entered: 08…2015 29 July 2016 1:15-cv-00536 830 Patent None District Court, D. Delaware	External link to document

Cephalon v. Fresenius Kabi: Litigation Summary, Bendamustine Patents, and Generic Entry Risk

Last updated: August 20, 2026

Cephalon, Inc. v. Fresenius Kabi USA, LLC, No. 1:15-cv-00536, was a Hatch-Waxman patent infringement action in the U.S. District Court for the District of Delaware involving generic bendamustine hydrochloride injection. Cephalon asserted patents covering pharmaceutical formulations of bendamustine, the active ingredient in Treanda and later Bendeka. The case was resolved without a reported merits judgment establishing infringement or invalidity. The principal commercial issue was whether Fresenius Kabi could obtain FDA approval and launch a competing bendamustine injectable product before expiration of Cephalon’s formulation patents.

What drug and patents were at issue in Cephalon v. Fresenius Kabi?

The litigation concerned bendamustine hydrochloride, an alkylating agent used primarily to treat chronic lymphocytic leukemia and indolent B-cell non-Hodgkin lymphoma.

Cephalon’s asserted patent estate focused on liquid bendamustine formulations rather than the basic bendamustine molecule. The core patents associated with the litigation were:

Patent	General subject matter	Patent holder or applicant associated with litigation	Expected expiration
U.S. Patent No. 8,445,524	Bendamustine pharmaceutical formulations	Cephalon, Inc.	January 28, 2031
U.S. Patent No. 8,609,863	Bendamustine formulations and related pharmaceutical compositions	Cephalon, Inc.	January 28, 2031

The patents claimed formulations intended to improve bendamustine’s stability and usability in an injectable product. The asserted technology was commercially important because the original Treanda product was supplied as a lyophilized powder, while newer products used liquid or ready-to-dilute presentations.

The case did not concern a biosimilar. Bendamustine is a small-molecule drug regulated through the abbreviated new drug application, or ANDA, pathway. Fresenius Kabi’s challenge therefore involved Hatch-Waxman procedures and a Paragraph IV certification, not the Biologics Price Competition and Innovation Act.

What was the procedural history of the Delaware patent case?

Cephalon filed the action in the District of Delaware in 2015 after Fresenius Kabi submitted an ANDA seeking approval to market a generic bendamustine hydrochloride injection.

The litigation followed the standard Hatch-Waxman sequence:

1. Fresenius Kabi submitted an ANDA for a generic bendamustine product.
2. The ANDA included a Paragraph IV certification challenging Cephalon’s listed formulation patents.
3. Cephalon filed an infringement complaint within the statutory 45-day period.
4. The filing triggered the automatic 30-month stay of FDA approval under 21 U.S.C. § 355(j)(5)(B)(iii), subject to statutory exceptions.
5. The parties litigated claim scope, infringement, validity, and the effect of any settlement or launch restrictions.
6. The action ended without a reported trial decision resolving the patents on the merits.

The public docket reflects a Hatch-Waxman dispute that concluded without a reported finding that Fresenius Kabi infringed the asserted claims or that Cephalon’s patents were invalid. The absence of a merits opinion limits the precedential value of the case.

What did Cephalon claim against Fresenius Kabi?

Cephalon alleged that Fresenius Kabi’s proposed generic product would infringe claims directed to bendamustine-containing pharmaceutical formulations.

The dispute likely centered on whether the ANDA product met limitations involving:

• Bendamustine hydrochloride concentration;
• Solvent composition;
• Use of alcohol-based and polyol-based excipients;
• Stability during storage;
• Injectable dosage-form characteristics; and
• Product preparation or dilution requirements.

In Hatch-Waxman litigation, the technical comparison is normally based on the ANDA specification, product composition, manufacturing information, and proposed labeling. A generic applicant can avoid infringement by designing around composition limitations, arguing that a claim is indefinite, or challenging validity based on anticipation or obviousness.

Because the case did not generate a reported final merits decision, there is no controlling judicial determination that Fresenius Kabi’s formulation fell within the asserted claims.

What was the Orange Book status of the bendamustine patents?

FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly called the Orange Book, is the principal source for listed patents and regulatory exclusivity associated with approved small-molecule products.

Bendamustine patents listed for Cephalon or its successor commercial interests were directed primarily to formulations and methods of use. The basic bendamustine compound patent was not the principal barrier by the time of the Fresenius Kabi case because compound-level protection had expired.

The relevant commercial distinction was:

Protection type	Status in the Fresenius Kabi dispute
Basic bendamustine compound protection	Expired or no longer a meaningful barrier
Injectable formulation patents	Principal litigation barrier
Method-of-use patents	Potentially relevant depending on ANDA labeling
Manufacturing know-how	Potential non-patent barrier
Regulatory exclusivity	Separate from patent protection and dependent on the approved product

Orange Book listing does not establish patent validity or infringement. It gives the reference-product sponsor a mechanism to identify patents that an ANDA applicant must address. The Paragraph IV certification then creates the basis for litigation.

When do Cephalon’s bendamustine formulation patents expire?

The principal patents associated with the dispute had an expected expiration date of January 28, 2031, based on the listed patent term and priority information. Any patent-term adjustment or pediatric exclusivity must be checked against the applicable FDA and USPTO records for the specific patent and product.

The practical exclusivity timeline was more complex than the patent expiration date:

Period	Commercial significance
Before ANDA filing	Cephalon controlled the approved bendamustine market subject to available competition
ANDA litigation period	FDA approval was generally subject to the statutory 30-month stay
Settlement or authorized-launch period	Entry timing depended on negotiated terms
After patent expiry	Unrestricted generic entry became possible, subject to FDA approval
After formulation patent expiry	Competitors could target the protected injectable formulation without that patent barrier

The formulation patents extended well beyond the expiration of the original compound patent. That structure allowed the sponsor to preserve protection around the commercial dosage form after molecule-level exclusivity ended.

Did Fresenius Kabi win or lose the patent case?

The case did not produce a publicly reported merits judgment awarding Cephalon damages or holding Fresenius Kabi’s ANDA product infringing. It also did not produce a reported invalidity judgment against the asserted patents.

The appropriate legal characterization is that the action was resolved procedurally rather than through a published trial ruling. A dismissal or settlement disposition does not establish that the patents were valid, that the proposed product infringed, or that Fresenius Kabi’s validity arguments would have succeeded.

For commercial analysis, the more important question was the launch date permitted under the parties’ resolution and the status of FDA approval. A settlement can preserve substantial patent value even when it does not result in a judicial ruling.

Was there a Paragraph IV challenge?

Yes. The litigation was an ANDA-related Paragraph IV dispute. Fresenius Kabi’s certification challenged Cephalon’s listed patents rather than accepting that the patents would block approval until expiration.

A Paragraph IV certification can assert that a listed patent is:

• Invalid;
• Unenforceable;
• Not infringed; or
• Not applicable to the proposed generic product.

The certification exposes the applicant to patent litigation but can accelerate market entry if the applicant prevails, reaches a settlement permitting launch, or obtains a final resolution that removes the regulatory stay.

The record does not support treating the case as a final judicial victory for either party. The commercial outcome must therefore be assessed through the settlement and FDA approval history rather than through a validity holding.

What formulation patents protected bendamustine?

The key formulation strategy was to protect a usable injectable presentation of bendamustine hydrochloride. Bendamustine has formulation challenges associated with stability and degradation. Formulation patents can claim the active ingredient together with selected solvents, excipients, concentrations, pH ranges, storage conditions, and dilution procedures.

The patent estate was directed at the product characteristics that determine whether a generic can provide:

• A liquid rather than lyophilized dosage form;
• A stable commercial product;
• A practical vial or ready-to-dilute presentation;
• A formulation compatible with intravenous administration; and
• A product with commercially acceptable shelf life.

This type of patent protection is usually stronger against literal copying than against carefully designed alternatives. Its value depends on how narrowly the claims define the formulation and whether the generic can use a different excipient system without sacrificing stability or manufacturing efficiency.

How strong was the Cephalon patent estate?

Cephalon’s estate was commercially meaningful but not equivalent to compound exclusivity.

Strengths

The estate had several advantages:

• It covered the commercial formulation rather than only a laboratory composition.
• The patents had long remaining terms during the 2015 litigation.
• Orange Book listing created a direct Hatch-Waxman enforcement route.
• A liquid formulation can be difficult to design around if stability depends on a narrow combination of excipients.
• The patents could delay approval even after the original bendamustine compound patent ceased to matter.

Weaknesses

The principal weaknesses were structural:

• Formulation claims can be vulnerable to obviousness challenges.
• Generic applicants can alter solvent systems, concentrations, or storage conditions.
• A formulation patent does not necessarily prevent all bendamustine products.
• The absence of a reported merits judgment means the asserted claims were not judicially validated in this case.
• A settlement can create an entry date that is earlier than patent expiration.

The overall estate should be classified as a formulation-based barrier with meaningful but product-specific blocking power. It was stronger against a close copy of the protected injectable presentation than against alternative bendamustine dosage forms.

What generic entry risks existed after the litigation?

The main generic entry risks were formulation substitution, settlement-based entry, and competition from products not covered by the asserted patents.

Generic launch scenarios

Scenario	Effect on Cephalon
Fresenius Kabi loses on infringement and validity issues	Delayed entry until patent expiry or negotiated date
Fresenius Kabi wins on non-infringement	Potential early entry with the proposed formulation
Fresenius Kabi invalidates the asserted claims	Broader generic entry risk for the protected formulation
Settlement permits a fixed launch date	Predictable erosion beginning on the agreed date
Alternative formulation receives approval	Competition despite continued validity of the asserted patents
Patent expiry occurs without further enforceable claims	Open generic entry for the covered product

Generic competition would likely pressure price and market share first in institutional oncology channels, where procurement decisions are sensitive to acquisition cost and supply reliability. The effect on branded sales would depend on whether the generic matched the reference product’s presentation, concentration, handling requirements, and reimbursement treatment.

What patent litigation affected Treanda and Bendeka?

The Cephalon-Fresenius Kabi case formed part of a broader patent strategy around bendamustine products. Cephalon developed Treanda, and Teva later acquired Cephalon and commercialized bendamustine products, including Bendeka.

Treanda and Bendeka had different commercial and technical profiles:

Product	Dosage-form profile	Patent strategy
Treanda	Primarily lyophilized bendamustine product	Product, formulation, and use protection
Bendeka	Ready-to-dilute liquid formulation	Liquid formulation and stability protection
Generic bendamustine	May use a different formulation or presentation	Paragraph IV and design-around strategies

Bendeka’s commercial value depended in part on formulation convenience and administration efficiency. A generic that avoided the asserted claims but required additional preparation could compete on price while offering a different operational profile.

How does this case compare with biosimilar litigation?

Cephalon v. Fresenius Kabi was not a biosimilar case. The distinction matters for regulatory and litigation analysis.

Issue	Bendamustine case	Biosimilar case
Regulatory pathway	ANDA	351(k) biologics license application
Product type	Small molecule	Biologic
Patent information	Orange Book	No equivalent Orange Book patent listing system
Certification	Paragraph IV	BPCIA patent-exchange procedures
Interchangeability	Therapeutic equivalence standards	Separate biosimilar or interchangeable designation
Main technical issue	Chemical formulation and dosage form	Molecular similarity, manufacturing, and biologic comparability

No biosimilar risk existed for bendamustine itself. The relevant competitive threat was generic drug entry.

What was the business impact of the litigation?

The litigation protected a product franchise whose value depended on formulation differentiation after compound-level exclusivity weakened.

Revenue exposure would have been concentrated in:

• Bendamustine product sales;
• Hospital and oncology-clinic purchasing;
• Reimbursement-driven substitution;
• Distribution agreements; and
• The value of Bendeka’s ready-to-dilute presentation.

The case’s commercial value to Cephalon was the potential to delay direct competition with the protected injectable formulation. Its value to Fresenius Kabi was the opportunity to obtain ANDA approval and enter a mature oncology market using established generic manufacturing and distribution capabilities.

The absence of a merits judgment reduced litigation precedent but did not eliminate economic significance. Settlement terms, launch timing, FDA approval, and the ability of other manufacturers to design around the claims remained the decisive factors.

What is the current litigation status of Cephalon v. Fresenius Kabi?

The action is closed. The docket does not show a reported final decision determining that the asserted bendamustine patents were infringed or invalid. The case should be treated as a resolved Hatch-Waxman dispute, not as a precedent establishing the enforceability of Cephalon’s formulation claims.

Subsequent diligence should distinguish this closed case from later litigation involving other bendamustine patents, products, manufacturers, or Teva entities. A settlement or dismissal in this action would not automatically resolve separate patents or separate ANDA products.

Key Takeaways

• Cephalon v. Fresenius Kabi involved generic bendamustine hydrochloride injection.
• The asserted patents were formulation patents, principally U.S. Patent Nos. 8,445,524 and 8,609,863.
• The patents were associated with liquid and injectable bendamustine formulations and had expected expiration dates in 2031.
• Fresenius Kabi’s ANDA included a Paragraph IV challenge.
• The case ended without a reported merits judgment on infringement or validity.
• The dispute was a small-molecule Hatch-Waxman case, not a biosimilar proceeding.
• Cephalon’s patent estate was strongest against close copies of the protected injectable formulation.
• Generic entry risk remained through settlement-based launch, design-around formulations, and later patent expiry.
• The principal commercial products were Treanda and Bendeka, later associated with Teva following its acquisition of Cephalon.

FAQs

What was the drug in Cephalon v. Fresenius Kabi?

The drug was bendamustine hydrochloride injection, an oncology product marketed in branded form as Treanda and later Bendeka.

Which Cephalon patents did Fresenius Kabi challenge?

The principal patents associated with the case were U.S. Patent Nos. 8,445,524 and 8,609,863, covering bendamustine pharmaceutical formulations.

Was Fresenius Kabi’s generic bendamustine approved by FDA?

The litigation record alone does not establish the ultimate approval and launch status for every Fresenius Kabi bendamustine product. FDA approval must be evaluated by the specific ANDA and product listing.

Did Cephalon obtain a permanent injunction?

There is no reported merits decision or permanent injunction establishing that Cephalon secured an injunction against Fresenius Kabi’s proposed product.

Did the case invalidate Cephalon’s bendamustine patents?

No reported decision in this action invalidated the asserted patents. The case ended without a published merits ruling resolving validity.

References

1. U.S. District Court for the District of Delaware. (2015). Cephalon, Inc. v. Fresenius Kabi USA, LLC, No. 1:15-cv-00536. PACER docket records.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA, Center for Drug Evaluation and Research.

3. U.S. Patent and Trademark Office. (2013). U.S. Patent No. 8,445,524: Bendamustine pharmaceutical formulations. U.S. Department of Commerce.

4. U.S. Patent and Trademark Office. (2013). U.S. Patent No. 8,609,863: Bendamustine pharmaceutical formulations. U.S. Department of Commerce.

5. Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355(j).